105 results about "Vasoconstriction" patented technology

A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other respiratory system therapies, radiation, chemotherapy, antibody therapy and surgery, among others. Each of the agents of this invention may be administered directly into the respiratory system so that they gain direct access to the lungs, or by other effective routes of administration. A kit comprises a delivery device, the agents and instructions for its use.

In certain example embodiments, an air delivery system includes a controllable flow generator operable to generate a supply of pressurized breathable gas to be provided to a patient for treatment and a pulse oximeter. In certain example embodiments, the pulse oximeter is configured to determine, for example, a measure of patient effort during a treatment period and provide a patient effort signal for input to control operation of the flow generator. Oximeter plethysmogram data may be used, for example, to determine estimated breath phase; sleep structure information; autonomic improvement in response to therapy; information relating to relative breathing effort, breathing frequency, and/or breathing phase; vasoconstrictive response, etc. Such data may be useful in diagnostic systems.

Lung volume reduction is performed by the placement of a device (2) into a branch of the airway (34) to prevent air from entering that portion of lung. This will result in adsorption atelectasis of the distal portion of lung. The physiological response in this portion of lung is hypoxic vaso-constriction. The net effect is for a portion of lung to be functionally removed, i.e. a selected portion of lung is removed from both the circulation and ventilation. The build up of secretions is accommodated by using a valve (5, 15, 29) in the obstructive device, the valve opening upon coughing etc.

The human heart is assisted in moving blood through blood vessels by alternately applying and relieving pressure about a blood vessel with a vessel constrictor. The blood flow is restricted to one direction along the blood vessel by restrictors. The application of pressure to the blood vessel may be timed with the heart beat.

The present invention provides a stent which is flexible in the axial direction prior to the expansion of the stent, which shows no contraction in the axial length of the stent during expansion of the stent, which has an extremely large resistance to forces exerted by contracting blood vessels after expansion, which can cause uniform expansion of the struts of the stent, and in which there is no problem of the end portions of the stent warping to a greater diameter than the central portion of the stent at the time of expansion, furthermore a stent in which the size of the basic cells that constitute the stent is reduced so that bulging of endothelial cells of vascular tissues into the inside of the stent is suppressed, furthermore a stent which allows Y stenting into branched blood vessels while maintaining a high radial force and superior scaffold properties.

A system and method for calculating the arterial compliance, stiffness, and arterial flow and resistance indices for any artery in issue of a subject having a blood pressure monitoring device configured to calculate systolic and diastolic blood pressure readings for an artery of the subject, a blood flow velocity monitoring device configured to calculate the velocity of blood flowing within the artery of the subject at a peak point of a systolic phase of contraction of the subject's heart muscle, peak-systolic velocity, and the velocity of blood flowing within the artery of the subject at an end point of a diastolic phase of the subject's heart muscle, end-diastolic velocity, and a central processing unit comprising a computer readable program embodied within the central processing unit configured to calculate the arterial compliance, stiffness, and arterial flow and resistance indices as a function of the area of the artery under initial systolic and end diastolic pressure, the area of the artery generating arterial elastic recoil pressure for continuous flow during the systolic and diastolic phases, peak-systolic and end-diastolic arterial flow velocities, and systolic and diastolic blood pressure.

An improved system and method for detecting a hypoglycemic event of a diabetic individual is provided. The system of the invention includes at least three sensors for monitoring the respective physiological parameter selected from the following list: heart rate, motorial activity, respiring rate, vasoconstriction, temperature of the skin and galvanic resistance of the skin of the user. The system automatically alerts the user and/or a member of medical care personnel in a case that at least three different symptoms of a hypoglycemic event, each of which associated with a respective physiological parameter, simultaneously occur. According to the method of the present invention basal levels and basal rates of changes of the respective physiological parameters are generated and repeatedly updated. These basal levels and/or rates provides for detecting changes that go beyond predefined limits for determining a symptom of a hypoglycemic event which is associated with the respective physiological parameter.

The invention discloses an intrauterine compression hemostasis method which comprises the following steps of: putting an elastic hemostasis bag in uterus, and filling low-temperature medium into the elastic hemostasis bag, wherein after the volume of the elastic hemostasis bag is expanded, the compression hemostasis is realized through the pressure of the elastic hemostasis bag on the inner wall of the uterus, and the vasoconstriction of the uterus is promoted by the low-temperature medium. A device realizing the method comprises the elastic hemostasis bag and a connection pipe, wherein the elastic hemostasis bag is provided with only one open end; the open end is in sealed connection with one end of the connection pipe; and a valve is arranged at one end of the connection pipe. The shape of the expanded elastic hemostasis bag is similar to that of the uterine cavity, and pressure in the uterine cavity is uniform; and when the pressure exceeds the systolic arterial pressure, a hemostasis effect is generated for sure. By monitoring the pressure, the autonomous uterine contraction can be discovered in time; and a temperature measuring device displays the change of water temperature, and the ice water can be replaced in time so as to avoid weakening of the hemostasis effect. According to the invention, the operation is simple, the monitoring is visual, the bleeding is minimized to a greatest extent, and the life safety of the patient is guaranteed.

The present invention discloses a compound hemostatic analgesic anti-inflammatory medicine for external application. It is made up by using (by weight portion) 0.05-5 portions of hemostatic, 0.005-0.02 portion of vasoconstrictor, 0.5-3.0 portions of narcotic and 0.1-5 portions of antimicrobial medicine. At the same time it can be made into various preparations for external application, including spray and powder for external application.

The present invention discloses a wearable health monitoring device. The wearable health monitoring device comprises a monitoring body, a wearable piece and a biological characteristic monitoring module; the wearable piece is connected to outside of the monitoring body; and the biological characteristic monitoring module is arranged in the monitoring body and comprises a photoelectric sensor, a pressure sensor and an air pressure sphygmomanometer, the air pressure sphygmomanometer is positioned in an embedding groove part of an embedding base body and comprises an air collection actuator and an elastic air bag, the air collection actuator supplies air to the elastic air bag, the elastic air bag is inflated to conduct elastic displacement to protrude out of the monitoring body and to be attached to skin tissues of users, the pressure sensor is also used to conduct blood vessel contraction pulsation quantity measurement under the skin tissues to generate detection signals and convert thedetection signals into health data information to be output, and the health data information provides monitoring correcting calculation of the photoelectric sensor to adjust and output the accurate health data information.

A method of testing a patient for hypertension includes providing a urine specimen from the patient, performing a first test on the urine specimen to determine if volume expansion hypertension exists by measuring the level of marinobufagenin in the urine specimen, performing a second test on the urine specimen to determine if vasoconstrictive hypertension exists by measuring the level of angiotensinogen in the urine specimen, and performing the first and second tests on the urine specimen substantially simultaneously without either test having an adverse effect on the other test. The tests may employ a test strip having a first region for use in the first test and a second region for use in the second test with each region effecting a visible change if the condition for which the test is being formed is found to exist. A related method of treatment and a related test kit are also disclosed.

An agent for the prophylaxis and treatment of vascular constriction is provided, which contains a compound having a Rho kinase inhibitory activity. In particular, a compound having a Rho kinase inhibitory activity, for example, (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane, suppresses regenerative intima proliferation after disorder of blood vessel and has various other actions. Therefore, it is useful as an agent for the prophylaxis and treatment of vascular constriction, specifically, an agent for the prophylaxis and treatment of vascular constriction induced by disorder of vascular wall, such as vascular restenosis that occurs after an operation of percutaneus transluminal coronary angioplasty, vascular restenosis that occurs after an operation of percutaneus transluminal angioplasty, vascular constriction that occurs after vascular reconstruction, such as DCA, operation of intravascular indwelling of stent and the like, and vascular constriction that occurs after organ transplantation.

The invention relates to the technical field of medicine and provides an application of chromane compound HEF-04 in relaxing blood vessel smooth muscle. In animal in vitro experiment, HEF-04 can relax rabbit in vitro blood vessel smooth muscle shrunk by barium chloride and potassium chloride; the vasodilation effect of chromane compound HEF-04 is not inhibited by the incubation of methylene blue, on the contrary, the blood vessel dose-effect curve shifts left due to higher level of potassium in spasm-induced agent; EC50 value has significant difference before and after the incubation. Documents report that the existence of NO and PGI2 can weaken the generation of EDHF; after NO and PGI2 are inhibited, the effect of endothelium-dependent vascular relaxation caused by EDHF is more prominent, showing that the vascular relaxation effect of HEF-04 is possibly related to the increase of EDHF releasing or caused by the interactions of vascular endothelium relaxing factors.

Contactless blood pressure monitoring, includes: illuminating a blood vessel of a patient with infrared (‘IR’) light; receiving, by an IR camera through a polarizing filter, IR light reflected by the patient; capturing at a time based on a heartrate of the patient, a first IR image of the blood vessel of the patient when the blood vessel is distended; determining, from the first image, a maximum diameter of the blood vessel; capturing at a time based on the heartrate of the patient, a second IR image of the blood vessel of the patient when the blood vessel is contracted; determining, from the second IR image, a minimum diameter of the blood vessel; and calculating blood pressure of the patient in dependence upon the maximum and minimum diameters of the blood vessel.

The invention provides a traditional Chinese medicine capsule for treating hypertension, which is prepared from the following raw materials in proportioning by weight: burdock, celery root, ginkgo leaf, pseudo-ginseng, Rhodiola rosea and Nodus Nelumbinis Rhizomatis. A preparation method for the traditional Chinese medicine capsule for treating the hypertension comprises the following steps: weighing all the raw materials according to the weight ratio of a formula; removing impurities and cleaning; slicing and drying; then, adding 5 times the volume of water and decocting for 8 hours on a slow fire; filtering; collecting a filtrate for later use; then, adding 2 times the volume of water to filter residues to decorate for 2 hours; discarding the filter residues and merging the filtrates of two times; heating, concentrating, drying, crushing and sieving by a 200-mesh screen; and encapsulating to form a capsule preparation, wherein the charge quantity of each capsule is 0.5g. The invention has the characteristics that the raw materials are easy to get; the traditional Chinese medicine capsule for treating the hypertension does not have toxic and side effects and has the effects of invigorating the circulation of blood, enhancing and softening blood vessels, regulating the supply and demand balance of target organs on blood oxygen, improving blood microcirculation and increasing blood supply amount per second of the heart brain, thereby, the dilatation and constriction loads of arterial blood vessels are reduced, and the hypertension is lowered. The invention has the characteristics that certain food does not need to be avoided; diet does not need to be controlled; the capsule does not need to be taken for a long time no matter is the medical history long or short; the hypertension does not relapse; the traditional Chinese medicine capsule for treating the hypertension has long-term stability and the like.

The invention provides application of pinoresinol in preparation of a medicine for inhibiting thrombosis, and relates to the field of chemical medicines. Specifically provided is the application of a compound shown by formula I, or a salt thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof in the preparation of the medicine for inhibiting thrombosis. The compound shown by the formula I is preferably pinoresinol. Researches find that the compound pinoresinol extracted from t. maculata machride can be used for inhibiting vasoconstriction and has a remarkable effect of relaxing blood vessels. Meanwhile, the compound pinoresinol has an inhibiting effect on thrombosis, the thrombosis inhibiting effect of low-dose pinoresinol is better than that of high-dose pinoresinol, the thrombosis inhibiting rate is as high as 76.92%, the excellent thrombosis inhibiting effect is achieved while the medicine using dose is reduced, and the medicine using safety is improved. The compound pinoresinol can be used for preparing the medicine for inhibiting thrombosis, is used for preventing or treating thromboembolic diseases, and has a good application prospect.

A composition and method of preparing the composition for rapid and effective hemostasis is provided. The composition includes a first agent to induce platelet plug formation, a second to induce vasoconstriction and a third agent for activation of coagulation cascade. The composition comprises of 0.01% to 5% of chitosan; 0.01% to 0.25% of potassium aluminum sulphate; and 0.01% to 0.25% calcium salt. The clotting time of the composition is in the range of 30s to 140s. A method of preparing the hemostatic composition is further disclosed. The composition is configured to control hemorrhage from oozing and pressured bleeding injury any site in human/animal body.